Eli Lilly Reports the CHMP’s Positive Opinion of Omvoh (Mirikizumab) to Treat Moderate to Severe Active Crohn's Disease
Shots:
- The CHMP has recommended Omvoh to treat mod. to sev. active Crohn’s disease unresponsive to conventional or biologic therapy (decision expected within 1-2mos.). Decision from other global regulatory bodies, incl. US & Japan, is anticipated in H1’25
- Opinion was based on P-III (VIVID-1) trial of mirikizumab (900mg, IV, wks.0, 4, 8 then 300mg, SC, Q4W from wks.12-52) vs PBO & ustekinumab in Crohn’s disease patients
- Study showed improvement in co-1EPs of composite endoscopic response & clinical remission plus 2EPs of steroid-free clinical remission & endoscopic outcomes at wks.12 & 52 as well as improved bowel urgency & histologic outcomes; safety aligned with its known profile in UC. Results were published in The Lancet
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports the P-III (EMBER-3) Trial Results of Imlunestrant to Treat ER+/HER2- Advanced Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
